Pharmaxis in trading halt

Company News

Pharmaxis Limited (ASX:PXS) shares have been placed in a trading halt, pending a release to the market on the outcome of a clinical trial.
 
The pharmaceuticals company says it’s received the results of a clinical trial of its product Bronchitol, known as B305.
 
The group says the trial was large and the results need detailed analysis.
 
Pharmaxis last traded at 31.5 cents.
 
Pharmaxis booked a net loss of $20.7 million in the first half of fiscal 2013.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.